

Become part of the community helping to address colorectal cancer care



Do you want to make a difference in the lives of people who are living with colorectal cancer (CRC)? Now you can by joining BESPOKE CRC — a new clinical study currently enrolling patients. This study will determine the effects of clinical outcomes using Signatera™, a simple blood test that measures how much cancer is left in the body after initial treatment. The information from this study may be used to help doctors address colorectal cancer care with future patients.

You may qualify if all of the following criteria apply:


- You are a stage II or III colorectal cancer patient.
- Your doctor selected you to receive the Signatera test as part of your routine care
- You are eligible for chemotherapy.
- You are able to tolerate blood draws from the arm.
- You are 18 years of age or older.

[Read More | natera.com/BESPOKE-CRC](https://natera.com/BESPOKE-CRC)

Talk to your doctor today about enrolling in BESPOKE CRC



Signatera™
Residual disease test (MRD)



Study name:
BESPOKE Study of ctDNA Guided Therapy in Colorectal Cancer

Study ID:
NCT04264702

Study sites are currently enrolling patients.

